References

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

10.1016/s0140-6736(20)31366-0 · 2020 · External reference

FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

10.1158/1078-0432.ccr-18-2743 · 2019 · External reference

KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma

10.1056/nejmoa1914347 · 2020 · External reference

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

10.1056/nejmoa1709866 · 2018 · External reference

CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease

10.1007/s11899-018-0470-x · 2018 · External reference

Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemiacellular kinetics of tisagenlecleucel in pediatric B-ALL

10.1158/1078-0432.ccr-18-0758 · 2018 · External reference

Immunogenicity of CAR T cells in cancer therapy

10.1038/s41571-021-00476-2 · 2021 · External reference

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

10.1038/s41591-019-0737-3 · 2020 · External reference

Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia

10.1158/1078-0432.ccr-19-1339 · 2020 · External reference

Safety and efficacy of humanized versus murinized CD19 and CD22 CAR T-cell cocktail therapy for refractory/relapsed B-cell lymphoma

10.3390/cells11244085 · 2022 · External reference

Phase I trial of humanized CD19 CART-cell therapy developed in india: safe, active and feasible for outpatient therapy

10.1182/blood-2022-166082 · 2022 · External reference

Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia

10.1200/jco.20.03458 · 2021 · External reference

Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed/refractory ALL

10.1158/1078-0432.ccr-22-2038 · 2023 · External reference

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

10.1182/bloodadvances.2020004106 · 2021 · External reference

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL

10.1182/blood-2015-12-686725 · 2016 · External reference

T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo

10.4049/jimmunol.146.12.4414 · 1991 · External reference

The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma

10.1158/2326-6066.cir-20-0236 · 2021 · External reference

Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting

10.1093/protein/10.8.959 · 1997 · External reference

Structure guided homology model based design and engineering of mouse antibodies for humanization

10.6026/97320630010180 · 2014 · External reference

Tabhu: tools for antibody humanization

10.1093/bioinformatics/btu667 · 2015 · External reference

Ligand selection by combination of recombinant and cell panning selection techniques

2022 · External reference

Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies

10.1158/2643-3230.bcd-21-0181 · 2022 · External reference

Quantitative prediction of 3D solution shape and flexibility of nucleic acid nanostructures

10.1093/nar/gkr1173 · 2012 · External reference

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

10.1110/ps.0239403 · 2003 · External reference

NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11

10.1093/nar/gkn202 · 2008 · External reference

Gapped sequence alignment using artificial neural networks: application to the MHC class I system

10.1093/bioinformatics/btv639 · 2016 · External reference

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method

10.1186/1471-2105-6-132 · 2005 · External reference

Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries

10.1186/1745-7580-4-2 · 2008 · External reference

HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1 allele and haplotype frequencies defined by next generation sequencing in a population of East Croatia blood donors

10.1038/s41598-020-62175-9 · 2020 · External reference

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

10.1016/j.ccr.2013.03.018 · 2013 · External reference

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8(+) central memory T cells manufactured at clinical scale

2012 · External reference

An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL

2024 · External reference

Limit-dilution assay and clonal expansion of all T-cells capable of proliferation

10.1016/0022-1759(82)90003-5 · 1982 · External reference

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells

10.1158/2326-6066.cir-14-0186 · 2015 · External reference

Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase

10.1016/j.ymthe.2017.06.008 · 2017 · External reference

Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo

10.1182/blood.v89.8.2635 · 1997 · External reference

Humanization of antibodies

2008 · External reference

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity

10.4049/jimmunol.173.12.7647 · 2004 · External reference

Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor–engineered T cells

10.1158/1078-0432.ccr-18-2559 · 2019 · External reference

Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice

10.1158/0008-5472.can-15-0159 · 2015 · External reference

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

10.1038/s41375-022-01585-2 · 2022 · External reference

Influence of protein fold stability on immunogenicity and its implications for vaccine design

10.1080/14760584.2017.1306441 · 2017 · External reference

CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients

10.1172/jci85309 · 2016 · External reference

CD19 CAR antigen engagement mechanisms and affinity tuning

2023 · External reference

Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia

10.1002/ajh.25235 · 2018 · External reference

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

10.1038/s41591-018-0146-z · 2018 · External reference

Tuning the antigen density requirement for CAR T-cell activity

10.1158/2159-8290.cd-19-0945 · 2020 · External reference

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

10.1038/nm.4441 · 2018 · External reference

Current concepts in the diagnosis and management of cytokine release syndrome

10.1182/blood-2014-05-552729 · 2014 · External reference